Ryvu Therapeutics S.A. (RVU.WA)
PLN 31.8
(0.47%)
PLN 31.8
(0.47%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -100.94 Million PLN | -64.89% |
| 2022 | -71.67 Million PLN | 7.95% |
| 2021 | -77.86 Million PLN | -116.86% |
| 2020 | -35.9 Million PLN | 20.45% |
| 2019 | -45.13 Million PLN | -231.63% |
| 2018 | -13.61 Million PLN | -207.69% |
| 2017 | 12.63 Million PLN | 1141.45% |
| 2016 | -1.21 Million PLN | -158.54% |
| 2015 | 2.07 Million PLN | -60.68% |
| 2014 | 5.27 Million PLN | 347.72% |
| 2013 | -2.12 Million PLN | 66.02% |
| 2012 | -6.26 Million PLN | 4.25% |
| 2011 | -6.54 Million PLN | -120.66% |
| 2010 | -2.96 Million PLN | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -26.32 Million PLN | 14.13% |
| 2024 Q2 | -32.78 Million PLN | -24.55% |
| 2023 Q2 | -31.64 Million PLN | -80.4% |
| 2023 Q1 | -17.54 Million PLN | -1096.31% |
| 2023 FY | -118.18 Million PLN | -64.89% |
| 2023 Q4 | -30.65 Million PLN | -26.2% |
| 2023 Q3 | -24.28 Million PLN | 23.24% |
| 2022 Q3 | -13.94 Million PLN | 63.4% |
| 2022 Q1 | -26.75 Million PLN | -64.59% |
| 2022 Q2 | -38.1 Million PLN | -42.41% |
| 2022 FY | -71.67 Million PLN | 7.95% |
| 2022 Q4 | -1.46 Million PLN | 89.49% |
| 2021 Q4 | -16.25 Million PLN | 30.8% |
| 2021 Q1 | -15.65 Million PLN | -36.1% |
| 2021 FY | -77.86 Million PLN | -116.86% |
| 2021 Q2 | -22.46 Million PLN | -43.52% |
| 2021 Q3 | -23.48 Million PLN | -4.55% |
| 2020 Q4 | -11.5 Million PLN | 6.92% |
| 2020 FY | -35.9 Million PLN | 20.45% |
| 2020 Q1 | -4.96 Million PLN | 54.09% |
| 2020 Q2 | -6.86 Million PLN | -38.3% |
| 2020 Q3 | -12.35 Million PLN | -79.87% |
| 2019 Q1 | -7.6 Million PLN | 14.84% |
| 2019 Q4 | -10.81 Million PLN | 18.76% |
| 2019 FY | -45.13 Million PLN | -231.63% |
| 2019 Q3 | -13.31 Million PLN | -51.7% |
| 2019 Q2 | -8.77 Million PLN | -15.47% |
| 2018 Q3 | -2.6 Million PLN | -115.99% |
| 2018 Q4 | -8.92 Million PLN | -242.97% |
| 2018 FY | -13.61 Million PLN | -207.69% |
| 2018 Q2 | -1.2 Million PLN | -37.9% |
| 2018 Q1 | -874.03 Thousand PLN | -161.18% |
| 2017 FY | 12.63 Million PLN | 1141.45% |
| 2017 Q3 | 678.02 Thousand PLN | -77.14% |
| 2017 Q1 | 7.56 Million PLN | 11794.89% |
| 2017 Q2 | 2.96 Million PLN | -60.8% |
| 2017 Q4 | 1.42 Million PLN | 110.7% |
| 2016 Q1 | -2.56 Million PLN | -8.03% |
| 2016 FY | -1.21 Million PLN | -158.54% |
| 2016 Q4 | 63.6 Thousand PLN | -97.86% |
| 2016 Q3 | 2.97 Million PLN | 276.02% |
| 2016 Q2 | -1.69 Million PLN | 34.0% |
| 2015 Q4 | -2.37 Million PLN | -264.08% |
| 2015 Q3 | 1.44 Million PLN | -23.04% |
| 2015 Q2 | 1.87 Million PLN | 67.62% |
| 2015 Q1 | 1.12 Million PLN | -30.76% |
| 2015 FY | 2.07 Million PLN | -60.68% |
| 2014 Q1 | 550.83 Thousand PLN | 27.71% |
| 2014 Q4 | 1.61 Million PLN | 4.45% |
| 2014 Q3 | 1.54 Million PLN | -0.15% |
| 2014 Q2 | 1.55 Million PLN | 181.8% |
| 2014 FY | 5.27 Million PLN | 347.72% |
| 2013 Q4 | 431.29 Thousand PLN | 163.25% |
| 2013 FY | -2.12 Million PLN | 66.02% |
| 2013 Q1 | -971.56 Thousand PLN | 49.4% |
| 2013 Q2 | -906.07 Thousand PLN | 6.74% |
| 2013 Q3 | -681.86 Thousand PLN | 24.74% |
| 2012 Q3 | -850.77 Thousand PLN | 55.57% |
| 2012 FY | -6.26 Million PLN | 4.25% |
| 2012 Q2 | -1.91 Million PLN | -21.34% |
| 2012 Q1 | -1.57 Million PLN | 0.0% |
| 2012 Q4 | -1.92 Million PLN | -125.68% |
| 2011 FY | -6.54 Million PLN | -120.66% |
| 2010 FY | -2.96 Million PLN | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Bioceltix S.A. | -15.81 Million PLN | -538.121% |
| BIOTON S.A. | 15.29 Million PLN | 760.007% |
| Captor Therapeutics Spolka Akcyjna | -73.01 Million PLN | -38.255% |
| Mabion S.A. | 55.06 Million PLN | 283.338% |
| Molecure S.A. | -22.1 Million PLN | -356.702% |
| NanoGroup S.A. | -7.9 Million PLN | -1177.515% |
| Pharmena S.A. | 34.87 Million PLN | 389.49% |
| Poltreg S.A. | -16.86 Million PLN | -498.672% |
| Pure Biologics Spólka Akcyjna | -31.71 Million PLN | -218.267% |
| Synthaverse S.A. | 8.64 Million PLN | 1267.434% |
| Urteste S.A. | -6.44 Million PLN | -1465.814% |